Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Binding protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Binding protein. Displaying page 7 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2015-000467-14 Sponsor Protocol Number: IEO223 Start Date*: Information not available in EudraCT
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Colorectal cancer, Vitamina D and microbiota: towards new preventive strategies. A double blind Phase II randomized trial, ColoViD
    Medical condition: Colon rectal cancer stage I - III
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001171 Adenocarcinoma of colon stage III LLT
    21.0 100000004864 10001170 Adenocarcinoma of colon stage II LLT
    21.0 100000004864 10001169 Adenocarcinoma of colon stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001956-40 Sponsor Protocol Number: PK_pregnancy Start Date*: 2023-03-05
    Sponsor Name:Medical University Vienna
    Full Title: Antibiotic pharmacokinetics in women with twin pregnancy
    Medical condition: The target population are twin pregnancy women that will deliver through c-section and that are receiving one or more of the included antibiotics.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002673-38 Sponsor Protocol Number: CRLX030A2211 Start Date*: 2015-11-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, crossover placebo-controlled Phase II study to assess the effect of serelaxin versus placebo on high sensitivity cardiac troponin I (hs-cTnI) release in pat...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002249-13 Sponsor Protocol Number: 3125001 Start Date*: 2019-02-04
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE...
    Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020219-35 Sponsor Protocol Number: Start Date*: 2011-07-18
    Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust
    Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI
    Medical condition: Cardiovascular disease - Acute coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000231-27 Sponsor Protocol Number: NN8640-4263 Start Date*: 2019-04-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Trial now transitioned) DK (Completed) AT (Trial now transitioned) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Trial now transitioned) PL (Trial now transitioned) HU (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002582-35 Sponsor Protocol Number: MCI-196-E16 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002581-12 Sponsor Protocol Number: MCI-196-E14 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000763-33 Sponsor Protocol Number: 20160283 Start Date*: 2017-12-01
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu...
    Medical condition: Steroid Refractory Chronic Graft versus Host Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004123-16 Sponsor Protocol Number: 2019nCoV-302 Start Date*: 2020-09-23
    Sponsor Name:Novavax, Inc.
    Full Title: A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ...
    Medical condition: Prevention of COVID-19 caused by SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005297-37 Sponsor Protocol Number: 3552 Start Date*: 2016-02-10
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq
    Medical condition: Human Immunodeficiency Virus
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10020434 Human immunodeficiency virus infection causing other specified conditions LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-000382-14 Sponsor Protocol Number: mRNA-1273-P203 Start Date*: 2023-12-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of...
    Medical condition: Coronavirus Disease 2019
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003002-27 Sponsor Protocol Number: MIT-Es001-C303 Start Date*: 2020-10-14
    Sponsor Name:Estetra SRL
    Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10030971 Oral contraceptive LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002392-27 Sponsor Protocol Number: A5481003 Start Date*: 2009-04-06
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMEN...
    Medical condition: Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) HU (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002379-40 Sponsor Protocol Number: CAFQ056B2278 Start Date*: 2012-01-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006498-49 Sponsor Protocol Number: 21103 Start Date*: 2022-08-18
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Medical condition: Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000232-10 Sponsor Protocol Number: NN8640-4245 Start Date*: 2019-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca...
    Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Trial now transitioned) PL (Completed) ES (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003561-17 Sponsor Protocol Number: ECP-002 Start Date*: 2013-08-09
    Sponsor Name:Edimer Pharmaceuticals, Inc.
    Full Title: A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogeniticy and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male inf...
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1....
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: Newborns, Under 18 Gender: Male
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022865-81 Sponsor Protocol Number: ALX-0061-1.1/10 Start Date*: 2011-03-02
    Sponsor Name:Ablynx NV
    Full Title: A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-003364-19 Sponsor Protocol Number: AI424376 Start Date*: 2009-01-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in...
    Medical condition: HIV, COMBINATION THERAPY
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 07:09:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA